About rare mutations and fusions in lung cancer
Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
LATEST UPDATES
-
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Sponsors
